Table 2.

– Univariate analysis of mortality in all patients and those with duration of symptoms of less than 8 days.

	All (n = 8,553)		Early cohort (n = 6,099)
	OR (95CI)	P	OR (95CI)	p
Sex (female)	0.783 (0.698–0.879)	<0.001	0.775 (0.681–0.882)	<0.001
Age (per year)	1.090 (1.084–1.096)	<0.001	1.082 (1.076–1.089)	<0.001
Race (Caucasian)	3.267 (2.499–4.272)	<0.001	3.715 (2.734–5.047)	<0.001
High blood pressure	2.833 (2.509–3.200)	<0.001	2.700 (2.354–3.097)	<0.001
Dementia	4.323 (3.715–5.031)	<0.001	3.704 (3.137–4.374)	<0.001
Immunosuppressive treatment	1.747 (1.431–2.134)	<0.001	1.656 (1.328–2.066)	<0.001
Charlson Comorbidity Index (per point)	1.334 (1.296–1.373)	<0.001	1.307 (1.265–1.349)	<0.001
Duration of symptoms (per day)	0.930 (0.918–0.943)	<0.001	0.907 (0.886–0.928)	<0.001
Cough	0.652 (0.576–0738)	<0.001	0.703 (0.612–0.806)	<0.001
Temperature (per °C)	1.088 (1.026–1.154)	0.005	1.069 (1.000–1.141)	0.049
Dyspnea	1.865 (1.653–2.104)	<0.001	1.828 (1.597–2.091)	<0.001
Confusion	5.341 (4.620–6.174)	<0.001	4.433 (3.774–5.208)	<0.001
Respiratory rate > 20 breaths/min	3.396 (3.020–3.819)	<0.001	3.239 (2.838–3.696)	<0.001
SaO₂/FiO₂ (per unit)	0.993 (0.992–0.993)	<0.001	0.993 (0.992–0.993)	<0.001
Lymphocytes (per cells x 10³/µL)	1.000 (1.000–1.000)	0.424	1.000 (1.000–1.000)	0.470
C-reactive protein (per mg/L)	1.005 (1.005–1.006)	<0.001	1.006 (1.005–1.006)	<0.001
Creatinine (per mg/dL)	1.789 (1.651–1.938)	<0.001	1.647 (1.515–1.792)	<0.001
Treatment with Hydroxychloroquine	0.447 (0.391–0.512)	<0.001	0.483 (0.416–0.562)	<0.001
Treatment with Interferon-β	2.094 (1.813–2.420)	<0.001	2.098 (1.787–2.463)	<0.001
Treatment with Remdesivir	1.096 (0.507–2.366)	0.816	0.871 (0.360–2.109)	0.760
Treatment with LPV/r	0.651 (0.581–0.729)	<0.001	0.705 (0.620–0.801)	<0.001

LPV/r: lopinavir/ritonavir. OR: odds ratio. 95CI: 95% confidence interval.